Digitoxin and a synthetic monosaccharide analog inhibit cell viability in lung cancer cells

Toxicology and Applied Pharmacology

Volumn 258, Issue 1, 2012, Pages 51-60

  Elbaz, Hosam A ^a   Stueckle, Todd A ^a,d   Wang, Hua Yu Leo ^b   O'Doherty, George A ^b   Lowry, David T ^d   Sargent, Linda M ^d   Wang, Liying ^d   Dinu, Cerasela Zoica ^c   Rojanasakul, Yon ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c West Virginia University   (United States)

^d NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Anti cancer drugs; D6 MA analog; Digitoxin; Increased potency; Sub therapeutic concentrations

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYTOCHROME C; D6 MA; DIGITOXIN; PROTEIN P53; SURVIVIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; CYTOTOXICITY; DOWN REGULATION; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CASPASE 9; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN B1; CYTOCHROMES C; DIGITOXIN; HUMANS; LUNG NEOPLASMS; PROTEIN KINASES; RHAMNOSE; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 84855431152     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.10.007     Document Type: Article

References (37)

1. Abbas T., Dutta A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 2009, 9:400-414.
2. Allan L.A., Clarke P.R. Phosphorylation of Caspase-9 by CDK1/Cyclin B1 protects mitotic cells against apoptosis. Mol. Cell 2007, 26:301-310.
3. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discov. 2008, 7:1001-1012.
4. Baggot J.D., Davis L.E. Plasma protein binding of digitoxin and digoxin in several mammalian species. Res. Vet. Sci. 1973, 15:81-87.
5. Bartek J., Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003, 3:421-429.
6. Daniel D., Süsal C., Kopp B., Opelz G., Terness P. Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives. Int. Immunopharmacol. 2003, 3:1791-1801.
7. Dickson M.A., Schwartz G.K. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 2009, 16:36-43.
8. Iyer A.K.V., Zhou M., Azad N., Elbaz H., Wang L., Rogalsky D.K., Rojanasakul Y., O'Doherty G.A., Langenhan J.M. A direct comparison of the anticancer activities of digitoxin MeON-Neoglycosides and O-Glycosides: oligosaccharide chain length-dependent induction of Caspase-9-mediated apoptosis. ACS Med. Chem. Lett. 2010, 1:326-330.
9. Kometiani P., Liu L., Askari A. Digitalis-induced signaling by Na+/K+-ATPase in human breast cancer cells. Mol. Pharmacol. 2005, 67:929-936.
10. Kumar R., Gururaj A.E., Barnes C.J. p21-activated kinases in cancer. Nat. Rev. Cancer 2006, 6:459-471.
11. Langenhan J.M., Engle J.M., Slevin L.K., Fay L.R., Lucker R.W., Smith K.R., Endo M.M. Modifying the glycosidic linkage in digitoxin analogs provides selective cytotoxins. Bioorg. Med. Chem. Lett. 2008, 18:670-673.
12. Lapenna S., Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 2009, 8:547-566.
13. Lawrence T.S. Ouabain sensitizes tumor cells but not normal cells to radiation. Int. J. Radiat. Oncol. Biol. Phys. 1988, 15:953-958.
14. Lohman J.J.H.M., Merkus F.W.H.M. Plasma protein binding of digitoxin and some other drugs in renal disease. Pharm. World Sci. 1987, 9:75-78.
15. López-Lázaro M. Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved. Expert Opin. Ther. Targets 2007, 11:1043-1053.
16. Lopez-Lazaro M., Pastor N., Azrak S.S., Ayuso M.J., Austin C.A., Cortes F. Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J. Nat. Prod. 2005, 68:1642-1645.
17. Mijatovic T., Op De Beeck A., Van Quaquebeke E., Dewelle J., Darro F., de Launoit Y., Kiss R. The cardenolide UNBS1450 is able to deactivate nuclear factor κB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol. Cancer Ther. 2006, 5:391-399.
18. Mita A.C., Mita M.M., Nawrocki S.T., Giles F.J. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 2008, 14:5000-5005.
19. Newman R.A., Yang P., Pawlus A.D., Block K.I. Cardiac glycosides as novel cancer therapeutic agents. Mol. Interv. 2008, 8:36-49.
20. O'Connor D.S., Grossman D., Plescia J., Li F., Zhang H., Villa A., Tognin S., Marchisio P.C., Altieri D.C. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl. Acad. Sci. 2000, 97:13103-13107.
21. Perne A., Muellner M.K., Steinrueck M., Craig-Mueller N., Mayerhofer J., Schwarzinger I., Sloane M., Uras I.Z., Hoermann G., Nijman S.M., Mayerhofer M. Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis. PLoS One 2009, 4:e8292.
22. Piao C.Q., Liu L., Zhao Y.L., Balajee A.S., Suzuki M., Hei T.K. Immortalization of human small airway epithelial cells by ectopic expression of telomerase. Carcinogenesis 2005, 26:725-731.
23. Roninson I.B. Oncogenic functions of tumour suppressor p21Waf1/Cip1/Sdi1: association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 2002, 179:1-14.
24. Schwartz G.K., Shah M.A. Targeting the cell cycle: a new approach to cancer therapy. J. Clin. Oncol. 2005, 23:9408-9421.
25. Smith T.W. The fundamental mechanism of inotropic action of digitalis. Therapie 1989, 44:431-435.
26. Stark G., Taylor W. Control of the G2/M transition. Mol. Biotechnol. 2006, 32:227-248.
27. Stenkvist B., Pengtsson E., Dahlqvist B., Eriksson O., Jarkrans T., Nordin B. Cardiac glycosides and breast cancer, revisited. N. Engl. J. Med. 1982, 306:484.
28. Vermeulen K., Van Bockstaele D.R., Berneman Z.N. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003, 36:131-149.
29. Wang Y., Ji P., Liu J., Broaddus R.R., Xue F., Zhang W. Centrosome-associated regulators of the G2/M checkpoint as targets for cancer therapy. Mol. Cancer 2009, 8:8.
30. Wang Z., Zheng M., Li Z., Li R., Jia L., Xiong X., Southall N., Wang S., Xia M., Austin C.P., Zheng W., Xie Z., Sun Y. Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition. Cancer Res. 2009, 69:6556-6564.
31. Wang H.-Y.L., Xin W., Zhou M., Stueckle T.A., Rojanasakul Y., O'Doherty G.A. Stereochemical survey of digitoxin monosaccharides. ACS Medicinal Chemistry Letters 2010, 2:73-78.
32. Wang H.-Y.L., Wu B., Zhang Q., Kang S.-W., Rojanasakul Y., O'Doherty G.A. C5'-alkyl substitution effects on digitoxigenin α-l-glycoside cancer cytotoxicity. ACS Medicinal Chemistry Letters 2011, 2:259-263.
33. Wang H.-Y.L., Rojanasakul Y., O'Doherty G.A. Synthesis and evaluation of the α-d-/α-l-rhamnosyl and amicetosyl digitoxigenin oligomers as antitumor agents. ACS Medicinal Chemistry Letters 2011, 2:264-269.
34. Xie Z., Cai T. Na+/K+ATPase-mediated signal transduction: from protein interaction to cellular function. Mol. Interv. 2003, 3:157-168.
35. Yuan J., Yan R., Kramer A., Eckerdt F., Roller M., Kaufmann M., Strebhardt K. Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene 2004, 23:5843-5852.
36. Zhou B.-B.S., Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat. Rev. Cancer 2004, 4:216-225.
37. Zhou M., O'Doherty G. The de novo synthesis of oligosaccharides: application to the medicinal chemistry SAR-study of digitoxin. Curr. Top. Med. Chem. 2008, 8:114-125.